论文部分内容阅读
从我国东南部所产的三尖杉植物中分离出主要含有高三尖杉酯碱和三尖杉酯碱混合物的两种制剂 ZJ-H 和 ZJ-C 经过临床前试验后,在临床上初次试用于不同年龄的急性白血病病人。主要的毒性副作用是白细胞减少和心肌损害。以这种药物2毫克/日或0.08毫克/公斤/日(儿童),或4毫克/日或0.15毫克/公斤/日(儿童)缓慢静脉滴注,连续给药,对大多数病人是安全而能接受的,并能引起急性白血病的完全缓解或部分缓解。超过上述每日剂量增加毒性反应的危险,而疗效不一定好。41个各种类型的急性白血病病人用两种方案三种剂量中的任何一种治疗,总的完全缓解率为12%,一级部分缓解率5%。在急粒、急粒单和急单白血病患者中的疗效尤其值得注意。如只考虑曾经采用较适当治疗方案(4毫克/日,静滴,连续给药)治疗的急性非淋巴性白血病病例,则完全缓解率为4/17(24%)总的有效率(完全缓解率十一级部分缓解率)为6/17(35%)。这一初步试探性的研究表明三尖杉酯碱和高三尖杉酯碱的混合物作为急性白血病的诱导治疗是有前途的,并值得在更多病人中作进一步的研究探索。
Two preparations ZJ-H and ZJ-C containing mainly mixtures of homoharringtonine and harringtonine were isolated from plants of cedarines produced in the southeast of China. After clinical trials, clinical trials were conducted. In different ages of acute leukemia patients. The main toxic side effects are leukopenia and myocardial damage. A continuous intravenous infusion of this drug at 2 mg/day or 0.08 mg/kg/day (children), or 4 mg/day or 0.15 mg/kg/day (children) for continuous administration is safe for most patients. Acceptable and can cause complete or partial remission of acute leukemia. Exceeding the above daily dose increases the risk of toxic reactions, and the efficacy is not necessarily good. Forty-one patients with various types of acute leukemia were treated with either regimen of three doses, with a total complete remission rate of 12% and a partial partial remission rate of 5%. The efficacy of acute granules, acute granules, and acute leukemia patients is particularly noteworthy. If only patients with acute non-lymphocytic leukemia who have been treated with a more appropriate treatment regimen (4 mg/day, intravenous drip, continuous dose) are considered, the complete response rate is 4/17 (24%) total response rate (complete response). The rate of partial remission at rate 11 is 6/17 (35%). This preliminary exploratory study shows that the mixture of harringtonine and homoharringtonine is promising as an induction therapy for acute leukemia, and worthy of further research and exploration in more patients.